Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System

The successful implementation of chimeric antigen receptor (CAR)-T cell therapy in the clinical context of B cell malignancies has paved the way for further development in the more critical setting of acute myeloid leukemia (AML). Among the potentially targetable AML antigens, CD33 is insofar one of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Ther
Auteurs principaux: Rotiroti, Maria Caterina, Buracchi, Chiara, Arcangeli, Silvia, Galimberti, Stefania, Valsecchi, Maria Grazia, Perriello, Vincenzo Maria, Rasko, Tamas, Alberti, Gaia, Magnani, Chiara Francesca, Cappuzzello, Claudia, Lundberg, Felix, Pande, Amit, Dastoli, Giuseppe, Introna, Martino, Serafini, Marta, Biagi, Ettore, Izsvák, Zsuzsanna, Biondi, Andrea, Tettamanti, Sarah
Format: Artigo
Langue:Inglês
Publié: American Society of Gene & Cell Therapy 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7474266/
https://ncbi.nlm.nih.gov/pubmed/32526203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.05.021
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires